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Cancer transformation involves reprograming of mitochondrial function to avert cell
death mechanisms, monopolize energy metabolism, accelerate mitotic proliferation, and
promote metastasis. Mitochondrial ion channels have emerged as promising therapeutic
targets because of their connection to metabolic and apoptotic functions. This mini review
discusses how mitochondrial channels may be associated with cancer transformation
and expands on the possible involvement of mitochondrial protein import complexes in
pathophysiological process.
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Introduction
The eukaryotic merger that gave rise to mitochondria was arguably the major contributor to the ori-
gin of multicellular organisms (1, 2), afforded by the increased efficiency in cellular energy conver-
sion. However, maintaining multicellular life required more than power. Mitochondria had to spe-
cialize in eliminatingmalfunctioning cells and policing unrestrained growth of once-single cells. An
insurgence against the newfound multicellular way of life would be punished with a death sentence.
Power, or a death sentence, is released from mitochondria through channels spanning the
inner and the outer membranes. For example, mitochondria deliver ATP and other high-energy
metabolites to the cell through a voltage-dependent anion channel [VDAC, reviewed in Ref. (3)],
while death signals like cytochrome c are unleashed through the mitochondrial apoptosis-induced
channel [MAC; (4)] (Figure 1). Comprehensive reviews on the structure–function relationships of
ion channels in mitochondria are available elsewhere (5–11). This mini review will focus on the
possible involvement of mitochondrial ion channels in cancer transformation.
If an insurgent cell is to survive, it must reprogram the power plant. Some cancer cells accomplish
this task by decreasing the open probability of mitochondrial channels involved in the transport of
energy metabolites (13–15) and relying on glycolytic metabolism to fuel competitive reproduction
(3).Onewould think that the payoff for relinquishing energy conversion efficiency is that cancer cells
suffer lower oxidative stress. However, oxidative stress seems to be one of the determinants of tumor
cell transformation (16, 17). As discussed below and elsewhere (18), respiring mitochondria are the
major sources of cytotoxic reactive oxygen species (ROS). Interestingly, exacerbated ROS emission
causes the opening of pores in the inner membrane that breach the permeability barrier to solutes
and the ensuing uncontrolled matrix swelling, membrane rupture, and spillage of mitochondrial
proteins into the cytosol. Although the exact mechanism of permeability transition of the inner
membrane is still being deciphered, cancer cells expertly avert them by equally mysterious ways.
Another feature of cancer mitochondria is that they are coated with sentinel proteins, which
prevent the formation ofMAC in the outermembrane, rendering the power plant oblivious to cancer
transformation and unrestrained growth. Interestingly, much of our current understanding about
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FIGURE 1 |Mitochondrial ion channels might mediate exchange of
oncogenic factors with the nucleus. Nuclear oncogenic factors either
directly (via nuclear pore complexes, NPC) (12) or indirectly (via oncogenic
expression) are transmitted to mitochondria to reprogram metabolism and cell
death mechanisms. Channels in the outer and the inner membranes might
provide the pathways for production and/or bi-directional transport of oncogenic
factors. Alternatively, they might be direct targets (see text). The legend indicates
channel components (red) or modulators (black) associated with cancer (see
text for references). Components and regulators of TIM22 and TIM23 channels
were listed in the same category. K+C represents the potassium channels BKCa
and IKCa, ATP-dependent KATP, Kv1.3, two-pore TWIK-related acid-sensitive
K+ channel-3 (TASK-3). Inspired by Odra Noel’s “Mitochondrial Dawn”.
the regulation of MAC arose from studying cancer cells, which
over express the sentinel protein Bcl-2. It may also sound counter-
intuitive that the MAC components Bax and Bak are structurally
related and belong to the Bcl-2 family of proteins. The truth is that
this multifaceted family of proteins controls permeabilization of
the outer membrane by either inducing or preventing it. In cancer
cells, the second mode prevails and might even go beyond the
outer membrane, as some anti-apoptotic members (Bcl-xL and
Mcl-1) have been shown to interact with and regulate inner mem-
brane proteins, including putative components of the permeability
transition pore complex (19–21).
Induction and maintenance of tumor transformation might
involve more than reprograming of metabolism and containment
of apoptotic signaling. Recent studies suggest that mitochondrial
dysfunctionmight be causally linked to the characteristic genomic
instability of many human cancer cells (22–27). One could
envision the involvement of additional mitochondrial channels
responsible for, e.g., control of calcium, potassium and mag-
nesium flux, organelle volume, and nucleic acid transport. The
development of new tools has enabled the identification of elusive
mitochondrial channels like the calcium uniporter (MCU) (28,
29), creating momentum for deeper understanding of the role
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of mitochondria in cancer cell transformation. Excellent reviews
have been recently published on the therapeutic potential of mito-
chondrial ion channels in cancer (30–32). This mini review will
focus on the putative role that these channels might exert on the
reciprocal transmission of oncogenic factors between mitochon-
dria and the nucleus (Figure 1).
Metabolic Channels
Voltage-Dependent Anion Channel
Sometimes coined the food channel, VDAC was discovered in
mitochondria almost 40 years ago (33). There is currently no
definitive evidence that indicates the steady state conformation
of VDAC in intact cells, but a pioneering study suggests an open
state (34). When fully open, VDAC allows the exchange of ATP
and ADP as well as electron transport chain substrates pyruvate,
malate, succinate, and NADH across the outer mitochondrial
membrane (35–41). In this state, the channel is normally slightly
anion-selective but becomes cation-selective in its half-open state,
possibly favoring calcium over metabolites (42). Interestingly,
this cationic conductance has also been observed when VDAC
is fully open (42), suggestive of a possible role in transport of
larger positively charged metabolites. Although more sporadic in
reconstituted systems, this behavior was observed in preparations
from yeast and mammalian VDAC and might explain the overall
positive net conductance of mitochondria (42–44). In mammals,
three isoforms of VDAC have been discovered: VDAC1, VDAC2,
and VDAC3 (45). These isoforms display similarities in both
structure and function, but each has been found to play a dis-
tinct role in mitochondria-mediated apoptosis and metabolism.
Little is known of the function of VDAC3, which is abundant
in sperm cells. Is any particular isoform up/down regulated in
different tumors? The answer seems to be yes, at least for VDAC1.
Recent studies found that the vdac1 gene is up regulated in breast,
colon, liver, lung, pancreatic, and thyroid cancer tissue (46, 47).
Knockdown of vdac1 caused slowed proliferation of HeLa cells
and reduced tumor size in vivo, suggesting a role of VDAC1 in the
loss of growth control commonly observed in cancer cells (48).
Another possible role for VDAC1may exist in tumor microen-
vironments, which are often hypoxic. VDAC1 with a truncated
C-terminus (VDAC1-∆C) has been identified in both cancer cell
lines and patient tumor tissue samples (41). VDAC1-∆C was
present in cancer cell lines that had high-cytoplasmic levels of
adenosine triphosphate and in lung cancer biopsies that showed
a strong resistance to chemotherapy-induced apoptosis (49).
Voltage-dependent anion channel has become an attractive
target for anticancer therapy due to its essential role in apoptosis
and metabolism, processes deregulated in cancer (50). Cancer
cells exhibit high levels of aerobic glycolysis, a phenomenon first
observed by Otto Warburg in 1956. The glycolytic enzyme hex-
okinase 2 (HK2), which is overexpressed in cancer cells, is a
key regulator of the Warburg effect and binds to VDAC, form-
ing HK–VDAC complexes (51). It remains to be determined if
HK2 binds to all VDAC isoforms. However, an additional link
to VDAC1 and VDAC2 involvement can be inferred from their
regulation by free tubulin, suggesting that it might underlie the
cytotoxic effect of chemotherapeutic drugs affecting microtubule
formation (15). It has also been recently suggested that the low-
ATP/ADP ratio resulting from free tubulin-mediated VDAC clo-
sure is a contributing factor to theWarburg effect (12–15).VDAC2
also regulates apoptosis through its interactions with Bak, namely,
the localization of Bak to the mitochondria and inhibition of
Bak-mediated apoptosis (49, 52). As demonstrated in melanoma
cells, overexpressing Bcl-xS disrupts the VDAC2-Bak interaction
by binding to VDAC2, releasing Bak, and allowing it to initiate
apoptosis (53). Less is known about interaction between VDAC2
and the primarily cytosolic Bcl-2 protein Bax, but recent studies
have shed some light on Bax regulation by VDAC2. Cells deficient
in Bak and VDAC2, but not Bax, displayed resistance to apoptotic
stimuli, suggesting a role for VDAC2 in Bax activation (54). More
recently, it has been shown that VDAC2 facilitates recruitment of
both Bak and Bax to the mitochondria and that VDAC2 and Bak
are required for Bax-mediated apoptosis (52, 53, 55).
Cell Death Channels
The two mitochondria-permeabilizing structures MAC and PTP
are considered to be the main death channels. Of note, these
two functional entities allow the release in the cytosol of mito-
chondrial factors such as cytochrome c during apoptosis and/or
necrosis (56).
Mitochondrial Apoptosis-Induced Channel
Broadly recognized as the main site through which death sig-
nals like cytochrome c are released into the cytosol, MAC is a
dynamic channel formed in the outer membrane by at least two
pro-apoptotic members of the Bcl-2 protein family, Bak and Bax
(57, 58). However, the MAC pore may not be entirely of protein
nature. Some studies showed that ceramides or intermediates of
ceramide biosynthesis pathway had the potential to stimulate
cytochrome c release in a Bak- and/or Bax-dependent fashion,
indicating that these lipids are potentially an integral part of
MAC (59, 60). In theory, MAC function antagonizes cancer cell
transformation and is, in fact, kept at bay by oncogenic gene
expression. Up regulation of the Bcl-2 or Bcl-xL proto-oncogenes
is associated with tumor formation and more particularly with
B-cell non-Hodgkin’s lymphoma (61–63). Pro-lymphocytic cell
lines overexpressing Bcl-2 exhibit resistance to MAC formation
and the ability to induce lymphoma in mice (44, 63–65). Para-
doxically, it was shown that an over-abundance of Bcl-2 not
only caused mitochondrial sequestration of BH3-only proteins,
which are activators of MAC formation, but also that of the MAC
core component Bax (66–68). This phenomenon seems to be a
common feature of anti-apoptotic Bcl-2 family members as an
over-abundance of Bcl-xL was also recently shown to induce both
Bax accumulation and functional activation at the mitochondria
(69, 70). This accumulation has been coined “priming for death,”
and this concept is currently being used to develop new cancer
therapies (66, 67). The first approach to pharmacologically trigger
Bax-mediated apoptosis in primed cancer cells comes from the
group of Stanley Korsmeyer. In one of these studies, a stabilized
stapled BIM helix peptide was even shown to efficiently com-
pete for binding to Bcl-2 with mitochondrial native BIM in a
model of hematologic cancer (71). Another approach taken was
to screen for small organic molecules, which can act as BH3
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mimetics on anti-apoptotic multi-domain Bcl-2 family members.
The first of these BH3 mimetic compounds to be developed was
ABT-737, which binds Bcl-2, Bcl-xL, and Bcl-w (69). An orally
bioavailable variant (ABT-263 or Navitoclax) was later developed
(12) with promising clinical trial results but the caveat of causing
thrombocytopenia (15).
ABT-199 is another recently developed drug that has shown
antitumor activity in vitro and in vivo (31) and is perhaps the
most promising BH3 mimetic. Unlike ABT-263 and ABT-737,
ABT-199 is Bcl-2 selective and does not seem to cause throm-
bocytopenia (72). Its efficacy was first demonstrated in chronic
lymphocytic leukemia (CLL), but its cytotoxic activity has since
been reported in T-cell acute lymphoblastic leukemia (T-ALL)
(73), acute myeloid leukemia (74), and chronic myeloid leukemia
(CML) progenitor cells (15). In the CML study, treatment with
ABT-199 in combination with the tyrosine kinase inhibitor
imatinib enhanced inhibitory effects. It has also been used in com-
bination with tamoxifen to induce apoptosis in estrogen receptor-
positive breast cancer cells, in which Bcl-2 is overexpressed (70).
ABT-199, alone or in combination with other anticancer agents,
represents a promising strategy against growth of Bcl-2 dependent
cancers.
Tumorigenesis and the accompanying resistance to apoptosis
can also be initiated by down-regulation of pro-apoptotic Bax and
Bak. In this case, the death program fails as MAC formation is
prevented by a lack of building blocks (75). Chemotherapies in
this latter case may involve the activation of Nur77 by the drug
3-Cl-AHPC; activation of Nur77 leading to the conversion of Bcl-
2 into a core component of a new type of cytochrome c release
channel (76).
PTP
The selective induction of permeability transition in the inner
membrane has obvious onco-therapeutic potential. However,
most cancer mitochondria seem to be desensitized to signals
that trigger permeability transition in normal mitochondria (dis-
cussed below). Interestingly, a high incidence of cancer is found
in transplant patients treated with cyclosporine A, an immuno-
suppressant known to inhibit permeability transition of the inner
membrane (77). Themechanisms of PTP inhibition in cancer cells
are expertly summarized in two recent reviews by the Pinton and
Bernardi groups: cancer cells down regulate PTP inducers (i.e.,
ROS and calcium), alter expression of chaperones that regulate
PTP opening, desensitize the channel through kinase signaling
pathways (GSK-3 and hexokinase II), leading to reduced mito-
chondrial oxidative phosphorylation regimes characterized by
high ATP/ADP ratios, low-inorganic phosphate, and high-ROS
levels (74, 78). Intriguingly, some of the currently proposed PTP
components seem to be up regulated in cancer cells. That is the
case, for example, for the c subunit of the ATP synthase (79).
Other studies showed that increased levels of the c subunit induce
cell death via PTP (80, 81). One possible explanation to this
seemingly discrepancy is that cancer cells initially benefit from
PTP function (mitochondrial dysfunction and ROS emission) to
generate genome instability. As the cancer phenotype strengthens,
PTP is silenced, possibly by a combination of the fourmechanisms
listed above, a process sometimes potentiated by an increase in
mitophagy (74). It should be noted, however, that the structural
composition of PTP is still a matter of debate and it might involve
interactions between cyclophilin D, the adenine nucleotide trans-
porter (ANT), the phosphate carrier (PiC), and the F1Fo ATP
synthase in the inner membrane (82, 83).
Protein Import Channels
Mitochondrial biogenesis relies on the import of over 99% of the
organelle proteome from the cytoplasm. The import pathway is
through water-filled channel complexes, namely, the translocase
of the outer membrane (TOM), and the translocases of the inner
membrane (TIM22, and TIM23) [for a comprehensive review, see
Ref. (84)]. The TIM23 channel was the first electrophysiological
demonstration of the link between protein import and water-
filled channels inmitochondria (85, 86) followed by reports on the
channel activity of TOM, the protein import complex of the outer
membrane (87, 88). These two channels enable the coordinated
passage of proteins across both membranes and into the matrix
space.
Translocase of the outer membrane channels act as gatekeep-
ers of protein import as they open in response to binding of
precursor proteins carrying a signal peptide (89). This signal
can be a cysteine motif (90), a presequence (91), or an internal
targeting element (92). Most of the precursor proteins pass the
outer membrane via the TOM complex. Precursors with cleav-
able N-terminal presequences are further sorted to the matrix
or inner membrane by TIM23. Precursors of β-barrel proteins
bind to small Tim chaperones in the inter membrane space
and are then inserted into the outer membrane via the sorting
and assembly machinery (SAM). If the precursor carries spe-
cific cysteine motifs, it will be transferred from TOM to the
MIA complex for sorting into the intermembrane space. Finally,
precursors of the metabolite carrier family are transferred via
the Tim chaperones to the TIM22 translocase which then medi-
ates their insertion into the inner membrane (93). A few α-
helical outer membrane proteins seem to be imported indepen-
dently from the TOM complex but may instead require the SAM
complex (94).
A number of subunits of the protein import machineries have
been found to be overexpressed in mitochondria of cancer cells,
including Timm17a, Tim9, Tim13, Tim8b, Tim22, Tom20, Tom70,
and Tom7 (79). While it might sound logical that enhanced
biogenesis of mitochondrial proteins during cancer transforma-
tion requires up-regulation of the protein import machiner-
ies, it is surprising that, out of the list mentioned above, the
only channel forming protein is Tim22. Another study found
splice variants of Tim44 in oncotic thyroid carcinomas and
suggests this TIM23 peripheral component might have a role
in cancer transformation possibly by induction of ROS pro-
duction or impairment of protein import (95). Furthermore,
metabolic reprograming during tumorigenesis often requires
redistribution of kinases or transcription factors to mitochon-
dria in a process that depends on the mitochondrial import
machinery (12–15).
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Translocase of the outer membrane complex proteins have been
shown to interact with both pro- and anti-apoptotic Bcl-2 family
proteins, but their role in mitochondrial apoptosis is unclear.
Tom22, essential for maintaining TOM structure, has been
established as the mitochondrial receptor of Bax (96). In HeLa
cells treated with the proteasome inhibitor celastrol, Tom22 was
up regulated, yet Bax translocation still occurred in the absence of
Tom22, Tom70, and Tom40 (97, 98). Interestingly, metaxins 1 and
2, components of the SAM complex, were found to be required for
Bak activation in TNF-induced apoptosis in Bax deficient glioma
cells (99).
Another TOM subunit, Tom20, might have a role in cancer
transformation via interactionwith the arylhydrocarbon receptor-
interacting protein (AIP) (100). AIP is also associated with the
inhibitor of apoptosis protein survivin, which localizes to the
mitochondria and when released in response to apoptotic stimuli,
prevents cell death by inhibiting caspase activation (101). Survivin
is overexpressed in cancer cells and its import into the mito-
chondria is mediated by the AIP–Tom20 complex; this pathway
may be a potential target for cancer cells (102), provided that the
AIP–survivin interaction can be specifically targeted, as AIP has
been shown to bind other mitochondrial pre-proteins (100).
Small Ion Channels
Voltage-dependent anion channel is thought to allow unre-
strained ion flux across the outer membrane. However, ion flow
is tightly regulated across the inner membrane as to allow the
vital establishment of the hydrogen proton gradient. Inner mem-
brane ion channels control metabolic pace, emission of ROS,
organelle volume, and other functions that seem to be modified
in cancer cells; they are therefore natural candidates for activity
modulation through cancer transformation. A non-exhaustive list
of potential targets includes mitochondrial potassium channels
[calcium-dependent BKCa and IKCa, ATP-dependent KATP, Kv1.3,
two-pore TWIK-related Acid-Sensitive K+ channel-3 (TASK-
3)], calcium uniporter MCU, magnesium channels (Mrs2), anion
channels (CLIC), and channel activities that await molecular
identification (mCs, AAA, ACA, and IMAC) (30–32).
Concluding Remarks
Mitochondrial ion channels are emerging as promising onco-
therapeutic targets. Compelling and mounting literature suggests
that reprogramed metabolic and apoptotic signaling from mito-
chondria is present in cancer cells and might underlie their char-
acteristic genome instability. The field should benefit from studies
that aim at identifying oncogenic factors that are either released
from mitochondria or that affect the function of these organelles.
Also helpful would be the ability tomanipulate specific mitochon-
drial functions in animal models of cancer cell transformation;
and new electrophysiological and imagery techniques allowing
live monitoring of mitochondrial channels in cancer cells. Can-
cer cell transformation, rather than being solely induced by the
nucleus or the mitochondria, might involve crosstalk between
these cellular compartments.
Acknowledgments
Thisworkwas supported byWeissman School ofArts& Sciences –
Baruch College startup funds to PP and by startup funds from
CSU-Fresno College of Science and Mathematics to LD.
References
1. Lane N. Power, Sex, and Suicide: Mitochondria and the Origin of Life. Oxford:
Oxford University Press (2005).
2. Lane N. Bioenergetic constraints on the evolution of complex life. Cold Spring
Harb Perspect Biol (2014) 6:a015982. doi:10.1101/cshperspect.a015982
3. Maldonado EN, Lemasters JJ. ATP/ADP ratio, the missed connection between
mitochondria and the Warburg effect. Mitochondrion (2014) 19(Pt A):78–84.
doi:10.1016/j.mito.2014.09.002
4. Dejean LM, Martinez-Caballero S, Kinnally KW. Is MAC the knife that cuts
cytochrome c from mitochondria during apoptosis? Cell Death Differ (2006)
13:1387–95. doi:10.1038/sj.cdd.4401949
5. Peixoto PM, Ryu SY, Kinnally KW. Mitochondrial ion channels as therapeutic
targets. FEBS Lett (2010) 584:2142–52. doi:10.1016/j.febslet.2010.02.046
6. Ryu SY, Beutner G, Dirksen RT, Kinnally KW, Sheu SS. Mitochondrial ryan-
odine receptors and other mitochondrial Ca2+ permeable channels. FEBS Lett
(2010) 584:1948–55. doi:10.1016/j.febslet.2010.01.032
7. Tomaskova Z, Ondrias K. Mitochondrial chloride channels – what are they
for? FEBS Lett (2010) 584:2085–92. doi:10.1016/j.febslet.2010.01.035
8. Colombini M. Mitochondrial outer membrane channels. Chem Rev (2012)
112:6373–87. doi:10.1021/cr3002033
9. Szabo I, Leanza L, Gulbins E, Zoratti M. Physiology of potassium channels
in the inner membrane of mitochondria. Pflugers Arch (2012) 463:231–46.
doi:10.1007/s00424-011-1058-7
10. Marchi S, Pinton P. The mitochondrial calcium uniporter complex: molecular
components, structure and physiopathological implications. J Physiol (2014)
592:829–39. doi:10.1113/jphysiol.2013.268235
11. Szabo I, Zoratti M. Mitochondrial channels: ion fluxes and more. Physiol Rev
(2014) 94:519–608. doi:10.1152/physrev.00021.2013
12. Simon DN, Rout MP. Cancer and the nuclear pore complex. Adv ExpMed Biol
(2014) 773:285–307. doi:10.1007/978-1-4899-8032-8_13
13. Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T, et al.
Methyl jasmonate binds to and detaches mitochondria-bound hexokinase.
Oncogene (2008) 27:4636–43. doi:10.1038/onc.2008.108
14. Rostovtseva TK, Bezrukov SM. VDAC inhibition by tubulin and its physio-
logical implications. Biochim Biophys Acta (2012) 1818:1526–35. doi:10.1016/
j.bbamem.2011.11.004
15. Maldonado EN, Sheldon KL, Dehart DN, Patnaik J, Manevich Y, Townsend
DM, et al. Voltage-dependent anion channels modulate mitochondrial
metabolism in cancer cells: regulation by free tubulin and erastin. J Biol Chem
(2013) 288:11920–9. doi:10.1074/jbc.M112.433847
16. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and
downsides of reactive oxygen species for cancer: the roles of reactive oxygen
species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal
(2012) 16:1295–322. doi:10.1089/ars.2011.4414
17. Yang Y, Karakhanova S, Werner J, Bazhin AV. Reactive oxygen species in
cancer biology and anticancer therapy. Curr Med Chem (2013) 20:3677–92.
doi:10.2174/0929867311320999165
18. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species
(ROS) and ROS-induced ROS release. Physiol Rev (2014) 94:909–50. doi:10.
1152/physrev.00026.2013
19. Vento MT, Zazzu V, Loffreda A, Cross JR, Downward J, Stoppelli MP, et al.
Praf2 is a novel Bcl-xL/Bcl-2 interacting protein with the ability to modulate
survival of cancer cells. PLoS One (2010) 5:e15636. doi:10.1371/journal.pone.
0015636
20. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, et al. Targeting Mcl-
1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 20:1397–411.
doi:10.1517/13543784.2011.609167
Frontiers in Oncology | www.frontiersin.org June 2015 | Volume 5 | Article 1205
Madamba et al. Mitochondrial channels and oncogenic factors
21. Arbel N, Ben-Hail D, Shoshan-Barmatz V. Mediation of the antiapoptotic
activity of Bcl-xL protein upon interaction with VDAC1 protein. J Biol Chem
(2012) 287:23152–61. doi:10.1074/jbc.M112.345918
22. Delsite R, Kachhap S, Anbazhagan R, Gabrielson E, Singh KK. Nuclear genes
involved in mitochondria-to-nucleus communication in breast cancer cells.
Mol Cancer (2002) 1:6. doi:10.1186/1476-4598-1-6
23. Rasmussen AK, Chatterjee A, Rasmussen LJ, Singh KK. Mitochondria-
mediated nuclear mutator phenotype in Saccharomyces cerevisiae. Nucleic
Acids Res (2003) 31:3909–17. doi:10.1093/nar/gkg446
24. Miceli MV, Jazwinski SM. Nuclear gene expression changes due to mito-
chondrial dysfunction in ARPE-19 cells: implications for age-related macular
degeneration. Invest Ophthalmol Vis Sci (2005) 46:1765–73. doi:10.1167/iovs.
04-1327
25. SinghKK,KulawiecM, Still I, DesoukiMM,Geradts J,Matsui S. Inter-genomic
cross talk between mitochondria and the nucleus plays an important role in
tumorigenesis. Gene (2005) 354:140–6. doi:10.1016/j.gene.2005.03.027
26. Kulawiec M, Safina A, Desouki MM, Still I, Matsui S, Bakin A, et al. Tumori-
genic transformation of human breast epithelial cells induced by mitochon-
drial DNA depletion. Cancer Biol Ther (2008) 7:1732–43. doi:10.4161/cbt.7.
11.6729
27. Porporato PE, Payen VL, Perez-Escuredo J, De Saedeleer CJ, Danhier P,
Copetti T, et al. A mitochondrial switch promotes tumor metastasis. Cell Rep
(2014) 8:754–66. doi:10.1016/j.celrep.2014.06.043
28. Baughman JM, Perocchi F, Girgis HS, Plovanich M, Belcher-Timme CA, San-
cak Y, et al. Integrative genomics identifies MCU as an essential component of
the mitochondrial calcium uniporter. Nature (2011) 476:341–5. doi:10.1038/
nature10234
29. De Stefani D, Raffaello A, Teardo E, Szabo I, Rizzuto R. A forty-kilodalton
protein of the inner membrane is themitochondrial calcium uniporter.Nature
(2011) 476:336–40. doi:10.1038/nature10230
30. Peixoto PM,Dejean LM, Kinnally KW. The therapeutic potential of mitochon-
drial channels in cancer, ischemia-reperfusion injury, and neurodegeneration.
Mitochondrion (2012) 12:14–23. doi:10.1016/j.mito.2011.03.003
31. Leanza L, Biasutto L, Manago A, Gulbins E, Zoratti M, Szabo I. Intracellular
ion channels and cancer. Front Physiol (2013) 4:227. doi:10.3389/fphys.2013.
00227
32. Leanza L, Zoratti M, Gulbins E, Szabo I. Mitochondrial ion channels as
oncological targets. Oncogene (2014) 33:5569–81. doi:10.1038/onc.2013.578
33. Schein SJ, Colombini M, Finkelstein A. Reconstitution in planar lipid bilayers
of a voltage-dependent anion-selective channel obtained from paramecium
mitochondria. J Membr Biol (1976) 30:99–120. doi:10.1007/BF01869662
34. Jonas EA, Buchanan J, Kaczmarek LK. Prolonged activation of mitochon-
drial conductances during synaptic transmission. Science (1999) 286:1347–50.
doi:10.1126/science.286.5443.1347
35. Holden MJ, Colombini M. The mitochondrial outer membrane channel,
VDAC, is modulated by a soluble protein. FEBS Lett (1988) 241:105–9. doi:10.
1016/0014-5793(88)81040-8
36. Liu MY, Colombini M. Regulation of mitochondrial respiration by control-
ling the permeability of the outer membrane through the mitochondrial
channel, VDAC. Biochim Biophys Acta (1992) 1098:255–60. doi:10.1016/
S0005-2728(05)80344-5
37. Blachly-Dyson E, Zambronicz EB, Yu WH, Adams V, McCabe ER, Adelman
J, et al. Cloning and functional expression in yeast of two human isoforms
of the outer mitochondrial membrane channel, the voltage-dependent anion
channel. J Biol Chem (1993) 268:1835–41.
38. Zizi M, Forte M, Blachly-Dyson E, Colombini M. NADH regulates the gating
of VDAC, the mitochondrial outer membrane channel. J Biol Chem (1994)
269:1614–6.
39. Ahmadzadeh M, Horng A, Colombini M. The control of mitochondrial
respiration in yeast: a possible role of the outer mitochondrial membrane.
Cell Biochem Funct (1996) 14:201–8. doi:10.1002/(SICI)1099-0844(199609)
14:3<201::AID-CBF673>3.0.CO;2-Q
40. Rostovtseva T, ColombiniM. ATP flux is controlled by a voltage-gated channel
from the mitochondrial outer membrane. J Biol Chem (1996) 271:28006–8.
doi:10.1074/jbc.271.45.28006
41. Sampson MJ, Lovell RS, Craigen WJ. Isolation, characterization, and map-
ping of two mouse mitochondrial voltage-dependent anion channel isoforms.
Genomics (1996) 33:283–8. doi:10.1006/geno.1996.0193
42. Pavlov E, Grigoriev SM, Dejean LM, Zweihorn CL, Mannella CA,
Kinnally KW. The mitochondrial channel VDAC has a cation-selective
open state. Biochim Biophys Acta (2005) 1710:96–102. doi:10.1016/j.bbabio.
2005.09.006
43. Campo ML, Kinnally KW, Tedeschi H. The effect of antimycin A on mouse
liver inner mitochondrial membrane channel activity. J Biol Chem (1992)
267:8123–7.
44. Pavlov EV, Priault M, Pietkiewicz D, Cheng EH, Antonsson B, Manon S, et al.
A novel, high conductance channel of mitochondria linked to apoptosis in
mammalian cells and Bax expression in yeast. J Cell Biol (2001) 155:725–31.
doi:10.1083/jcb.200107057
45. Quast SA, Berger A, Buttstadt N, Friebel K, Schonherr R, Eberle J. General
sensitization ofmelanoma cells for TRAIL-induced apoptosis by the potassium
channel inhibitor TRAM-34 depends on release of SMAC. PLoS One (2012)
7:e39290. doi:10.1371/journal.pone.0039290
46. Rusznak Z, Bakondi G, Kosztka L, Pocsai K, Dienes B, Fodor J, et al. Mito-
chondrial expression of the two-pore domain TASK-3 channels in malig-
nantly transformed and non-malignant human cells. Virchows Arch (2008)
452:415–26. doi:10.1007/s00428-007-0545-x
47. Leanza L, Henry B, Sassi N, Zoratti M, Chandy KG, Gulbins E, et al. Inhibitors
of mitochondrial Kv1.3 channels induce Bax/Bak-independent death
of cancer cells. EMBO Mol Med (2012) 4:577–93. doi:10.1002/emmm.
201200235
48. Kosztka L, Rusznak Z, Nagy D, Nagy Z, Fodor J, Szucs G, et al. Inhibi-
tion of TASK-3 (KCNK9) channel biosynthesis changes cell morphology and
decreases both DNA content and mitochondrial function of melanoma cells
maintained in cell culture. Melanoma Res (2011) 21:308–22. doi:10.1097/
CMR.0b013e3283462713
49. Brahimi-Horn MC, Mazure NM. Hypoxic VDAC1: a potential mitochondrial
marker for cancer therapy. Adv Exp Med Biol (2014) 772:101–10. doi:10.1007/
978-1-4614-5915-6_5
50. Leanza L, Venturini E, Kadow S, Carpinteiro A, Gulbins E, Becker KA. Target-
ing a mitochondrial potassium channel to fight cancer. Cell Calcium (2014).
doi:10.1016/j.ceca.2014.09.006
51. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, et al.
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor
growth in human glioblastoma multiforme. J Exp Med (2011) 208:313–26.
doi:10.1084/jem.20101470
52. Ma SB, Nguyen TN, Tan I, Ninnis R, Iyer S, Stroud DA, et al. Bax targets
mitochondria by distinct mechanisms before or during apoptotic cell death: a
requirement for VDAC2 or Bak for efficient Bax apoptotic function.Cell Death
Differ (2014) 21:1925–35. doi:10.1038/cdd.2014.119
53. Roy SS, Ehrlich AM, Craigen WJ, Hajnoczky G. VDAC2 is required for
truncated BID-induced mitochondrial apoptosis by recruiting BAK to the
mitochondria. EMBO Rep (2009) 10:1341–7. doi:10.1038/embor.2009.219
54. Yamagata H, Shimizu S, Nishida Y, Watanabe Y, Craigen WJ, Tsujimoto Y.
Requirement of voltage-dependent anion channel 2 for pro-apoptotic activity
of Bax. Oncogene (2009) 28:3563–72. doi:10.1038/onc.2009.213
55. Leanza L, O’Reilly P, Doyle A, Venturini E, Zoratti M, Szegezdi E, et al.
Correlation between potassium channel expression and sensitivity to drug-
induced cell death in tumor cell lines. Curr Pharm Des (2014) 20:189–200.
doi:10.2174/13816128113199990032
56. Kinnally KW, Peixoto PM, Ryu SY, Dejean LM. Is mPTP the gatekeeper
for necrosis, apoptosis, or both? Biochim Biophys Acta (2011) 1813:616–22.
doi:10.1016/j.bbamcr.2010.09.013
57. Dejean LM, Martinez-Caballero S, Guo L, Hughes C, Teijido O, Ducret T,
et al. Oligomeric Bax is a component of the putative cytochrome c release
channelMAC,mitochondrial apoptosis-induced channel.Mol Biol Cell (2005)
16:2424–32. doi:10.1091/mbc.E04-12-1111
58. Martinez-Caballero S, Dejean LM, Kinnally MS, Oh KJ, Mannella CA, Kin-
nally KW. Assembly of the mitochondrial apoptosis-induced channel, MAC.
J Biol Chem (2009) 284:12235–45. doi:10.1074/jbc.M806610200
59. Siskind LJ, Mullen TD, Romero Rosales K, Clarke CJ, Hernandez-Corbacho
MJ, Edinger AL, et al. The BCL-2 protein BAK is required for long-chain
ceramide generation during apoptosis. J Biol Chem (2010) 285:11818–26.
doi:10.1074/jbc.M109.078121
60. Chipuk JE, McStay GP, Bharti A, Kuwana T, Clarke CJ, Siskind LJ, et al.
Sphingolipid metabolism cooperates with BAK and BAX to promote the
Frontiers in Oncology | www.frontiersin.org June 2015 | Volume 5 | Article 1206
Madamba et al. Mitochondrial channels and oncogenic factors
mitochondrial pathway of apoptosis. Cell (2012) 148:988–1000. doi:10.1016/j.
cell.2012.01.038
61. Egle A, Harris AW, Bath ML, O’Reilly L, Cory S. VavP-Bcl2 transgenic mice
develop follicular lymphoma preceded by germinal center hyperplasia. Blood
(2004) 103:2276–83. doi:10.1182/blood-2003-07-2469
62. Swanson PJ, Kuslak SL, Fang W, Tze L, Gaffney P, Selby S, et al. Fatal acute
lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and
c-myc. J Immunol (2004) 172:6684–91. doi:10.4049/jimmunol.172.11.6684
63. Meijerink JP, Van Lieshout EM, Beverloo HB, Van Drunen E, Mensink EJ,
Macville M, et al. Novel murine B-cell lymphoma/leukemia model to study
BCL2-driven oncogenesis. Int J Cancer (2005) 114:917–25. doi:10.1002/ijc.
20822
64. Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K, et al.
Regulated targeting of BAX to mitochondria. J Cell Biol (1998) 143:207–15.
doi:10.1083/jcb.143.1.207
65. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX
results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J
(1998) 17:3878–85. doi:10.1093/emboj/17.14.3878
66. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong
SA, et al. Mitochondria primed by death signals determine cellular addiction
to antiapoptotic BCL-2 family members. Cancer Cell (2006) 9:351–65. doi:10.
1016/j.ccr.2006.03.027
67. Letai AG. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis.
Nat Rev Cancer (2008) 8:121–32. doi:10.1038/nrc2297
68. Teijido O, Dejean L. Upregulation of Bcl2 inhibits apoptosis-driven BAX
insertion but favors BAX relocalization in mitochondria. FEBS Lett (2010)
584:3305–10. doi:10.1016/j.febslet.2010.07.002
69. Gautier F, Guillemin Y, Cartron PF, Gallenne T, Cauquil N, Le Diguarher
T, et al. Bax activation by engagement with, then release from, the BH3
binding site of Bcl-xL. Mol Cell Biol (2011) 31:832–44. doi:10.1128/MCB.
00161-10
70. Renault TT, Teijido O, Antonsson B, Dejean LM, Manon S. Regulation of
Bax mitochondrial localization by Bcl-2 and Bcl-x(L): keep your friends close
but your enemies closer. Int J Biochem Cell Biol (2013) 45:64–7. doi:10.1016/j.
biocel.2012.09.022
71. LaBelle JL, Katz SG, Bird GH, Gavathiotis E, Stewart ML, Lawrence C, et al. A
stapled BIM peptide overcomes apoptotic resistance in hematologic cancers.
J Clin Invest (2012) 122:2018–31. doi:10.1172/JCI46231
72. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson
R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its
normalization promotes apoptosis and inhibits cancer growth. Cancer Cell
(2007) 11:37–51. doi:10.1016/j.ccr.2006.10.020
73. Opalinska M, Meisinger C. Metabolic control via the mitochondrial protein
import machinery.Curr Opin Cell Biol (2015) 33:42–8. doi:10.1016/j.ceb.2014.
11.001
74. Bonora M, Pinton P. The mitochondrial permeability transition pore and
cancer: molecular mechanisms involved in cell death. Front Oncol (2014)
4:302. doi:10.3389/fonc.2014.00302
75. Reed JC. Bcl-2-family proteins and hematologic malignancies: history and
future prospects. Blood (2008) 111:3322–30. doi:10.1182/blood-2007-09-
078162
76. Han YH, Cao X, Lin B, Lin F, Kolluri SK, Stebbins J, et al. Regulation of
Nur77 nuclear export by c-Jun N-terminal kinase and Akt. Oncogene (2006)
25:2974–86. doi:10.1038/sj.onc.1209358
77. Norman KG, Canter JA, Shi M, Milne GL, Morrow JD, Sligh JE. Cyclosporine
A suppresses keratinocyte cell death through MPTP inhibition in a model for
skin cancer in organ transplant recipients. Mitochondrion (2010) 10:94–101.
doi:10.1016/j.mito.2009.10.001
78. Rasola A, Bernardi P. The mitochondrial permeability transition pore and
its adaptive responses in tumor cells. Cell Calcium (2015). doi:10.1016/j.ceca.
2015.03.004
79. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Salem AF, Tsirigos
A, Lamb R, et al. Mitochondria “fuel” breast cancer metabolism: fifteen mark-
ers of mitochondrial biogenesis label epithelial cancer cells, but are excluded
from adjacent stromal cells. Cell Cycle (2012) 11:4390–401. doi:10.4161/cc.
22777
80. Bonora M, Bononi A, De Marchi E, Giorgi C, Lebiedzinska M, Marchi S, et al.
Role of the c subunit of the FO ATP synthase in mitochondrial permeability
transition. Cell Cycle (2013) 12:674–83. doi:10.4161/cc.23599
81. Alavian KN, Beutner G, Lazrove E, Sacchetti S, Park HA, Licznerski P, et al. An
uncoupling channel within the c-subunit ring of the F1FOATP synthase is the
mitochondrial permeability transition pore. Proc Natl Acad Sci U S A (2014)
111:10580–5. doi:10.1073/pnas.1401591111
82. Halestrap AP. The C ring of the F1Fo ATP synthase forms the mitochondrial
permeability transition pore: a critical appraisal. Front Oncol (2014) 4:234.
doi:10.3389/fonc.2014.00234
83. Halestrap AP, Richardson AP. The mitochondrial permeability transition: a
current perspective on its identity and role in ischaemia/reperfusion injury.
J Mol Cell Cardiol (2015) 78:129–41. doi:10.1016/j.yjmcc.2014.08.018
84. Schmidt O, Pfanner N, Meisinger C. Mitochondrial protein import: from
proteomics to functionalmechanisms.Nat RevMol Cell Biol (2010) 11:655–67.
doi:10.1038/nrm2959
85. Lohret TA, Jensen RE, Kinnally KW. Tim23, a protein import component
of the mitochondrial inner membrane, is required for normal activity of the
multiple conductance channel, MCC. J Cell Biol (1997) 137:377–86. doi:10.
1083/jcb.137.2.377
86. Truscott KN, Kovermann P, Geissler A, Merlin A, Meijer M, Driessen AJ, et al.
A presequence- and voltage-sensitive channel of the mitochondrial preprotein
translocase formed by Tim23. Nat Struct Biol (2001) 8:1074–82. doi:10.1038/
nsb726
87. Hill K, Model K, Ryan MT, Dietmeier K, Martin F, Wagner R, et al. Tom40
forms the hydrophilic channel of the mitochondrial import pore for prepro-
teins [see comment]. Nature (1998) 395:516–21. doi:10.1038/26780
88. Kunkele KP, Heins S, Dembowski M, Nargang FE, Benz R, Thieffry M, et al.
The preprotein translocation channel of the outer membrane of mitochondria.
Cell (1998) 93:1009–19. doi:10.1016/S0092-8674(00)81206-4
89. Andreoli C, Prokisch H, Hortnagel K, Mueller JC, Munsterkotter M,
Scharfe C, et al. MitoP2, an integrated database on mitochondrial proteins
in yeast and man. Nucleic Acids Res (2004) 32:D459–62. doi:10.1093/nar/
gkh137
90. Herrmann JM,Hell K. Chopped, trapped or tacked – protein translocation into
the IMS of mitochondria. Trends Biochem Sci (2005) 30:205–11. doi:10.1016/
j.tibs.2005.02.005
91. Roise D, Schatz G. Mitochondrial presequences. J Biol Chem (1988)
263:4509–11.
92. Brix J, Rudiger S, Bukau B, Schneider-Mergener J, Pfanner N. Distribu-
tion of binding sequences for the mitochondrial import receptors Tom20,
Tom22, and Tom70 in a presequence-carrying preprotein and a non-
cleavable preprotein. J Biol Chem (1999) 274:16522–30. doi:10.1074/jbc.274.
23.16522
93. Peixoto PM, Grana F, Roy TJ, Dunn CD, Flores M, Jensen RE, et al. Awaking
TIM22, a dynamic ligand-gated channel for protein insertion in themitochon-
drial inner membrane. J Biol Chem (2007) 282:18694–701. doi:10.1074/jbc.
M700775200
94. Stojanovski D, Guiard B, Kozjak-Pavlovic V, Pfanner N, Meisinger C.
Alternative function for the mitochondrial SAM complex in biogenesis of
alpha-helical TOM proteins. J Cell Biol (2007) 179:881–93. doi:10.1083/jcb.
20070604320071212c
95. Handa N, Kishishita S, Morita S, Akasaka R, Jin Z, Chrzas J, et al. Structure of
the human Tim44 C-terminal domain in complex with pentaethylene glycol:
ligand-bound form. Acta Crystallogr D Biol Crystallogr (2007) 63:1225–34.
doi:10.1107/S0907444907051463
96. Bellot G, Cartron PF, Er E, Oliver L, Juin P, Armstrong LC, et al. TOM22, a
core component of the mitochondria outer membrane protein translocation
pore, is a mitochondrial receptor for the proapoptotic protein Bax. Cell Death
Differ (2007) 14:785–94. doi:10.1038/sj.cdd.4402055
97. Ross K, Rudel T, Kozjak-Pavlovic V. TOM-independent complex forma-
tion of Bax and Bak in mammalian mitochondria during TNF[alpha]-
induced apoptosis.Cell DeathDiffer (2009) 16:697–707. doi:10.1038/cdd.2008.
194
98. Feng L, Zhang D, Fan C, Ma C, Yang W, Meng Y, et al. ER stress-mediated
apoptosis induced by celastrol in cancer cells and important role of glycogen
synthase kinase-3[beta] in the signal network. Cell Death Dis (2013) 4:e715.
doi:10.1038/cddis.2013.222
99. Cartron P-F, Petit E, Bellot G, Oliver L, Vallette FM. Metaxins 1 and 2, two
proteins of the mitochondrial protein sorting and assembly machinery, are
essential for Bak activation during TNF alpha triggered apoptosis. Cell Signal
(2014) 26:1928–34. doi:10.1016/j.cellsig.2014.04.021
Frontiers in Oncology | www.frontiersin.org June 2015 | Volume 5 | Article 1207
Madamba et al. Mitochondrial channels and oncogenic factors
100. YanoM, Terada K,MoriM. AIP is amitochondrial import mediator that binds
to both import receptor Tom20 and preproteins. J Cell Biol (2003) 163:45–56.
doi:10.1083/jcb.200305051
101. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial sur-
vivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest (2004)
114:1117–27. doi:10.1172/JCI22222
102. Kang BH, Xia F, PopR,Dohi T, SocolovskyM,Altieri DC.Developmental con-
trol of apoptosis by the immunophilin aryl hydrocarbon receptor-interacting
protein (AIP) involves mitochondrial import of the survivin protein. J Biol
Chem (2011) 286:16758–67. doi:10.1074/jbc.M110.210120
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Madamba, Damri, Dejean and Peixoto. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Oncology | www.frontiersin.org June 2015 | Volume 5 | Article 1208
